FY2025 EPS Estimates for Pfizer Increased by Leerink Partnrs

Pfizer Inc. (NYSE:PFE) – Equities researchers at Leerink Partnrs lifted their FY2025 earnings per share (EPS) estimates for Pfizer in a note issued to investors on Wednesday, December 18th. Leerink Partnrs analyst D. Risinger now forecasts that the biopharmaceutical company will earn $2.90 per share for the year, up from their prior estimate of $2.82. The consensus estimate for Pfizer’s current full-year earnings is $2.95 per share.

Other equities analysts have also issued reports about the stock. StockNews.com lowered shares of Pfizer from a “strong-buy” rating to a “buy” rating in a report on Wednesday, November 20th. Wolfe Research started coverage on Pfizer in a research note on Friday, November 15th. They set an “underperform” rating and a $25.00 price target on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $45.00 price objective on shares of Pfizer in a research note on Wednesday, October 23rd. Sanford C. Bernstein initiated coverage on Pfizer in a research note on Thursday, October 17th. They set a “market perform” rating and a $32.00 target price on the stock. Finally, Citigroup began coverage on Pfizer in a research report on Friday, October 25th. They issued a “neutral” rating and a $30.00 target price for the company. One equities research analyst has rated the stock with a sell rating, nine have issued a hold rating, six have given a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat, Pfizer presently has a consensus rating of “Moderate Buy” and a consensus price target of $32.14.

Pfizer Trading Up 2.3 %

NYSE PFE opened at $26.36 on Monday. Pfizer has a 12 month low of $24.48 and a 12 month high of $31.54. The stock has a market capitalization of $149.38 billion, a P/E ratio of 35.62, a PEG ratio of 0.63 and a beta of 0.65. The firm’s 50-day moving average is $26.82 and its two-hundred day moving average is $28.17. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 EPS for the quarter, beating the consensus estimate of $0.64 by $0.42. The business had revenue of $17.70 billion for the quarter, compared to analyst estimates of $14.92 billion. Pfizer had a return on equity of 16.28% and a net margin of 7.07%. The company’s quarterly revenue was up 31.2% on a year-over-year basis. During the same quarter in the prior year, the company posted ($0.17) EPS.

Pfizer Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, March 7th. Stockholders of record on Friday, January 24th will be issued a $0.43 dividend. The ex-dividend date of this dividend is Friday, January 24th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.53%. This is an increase from Pfizer’s previous quarterly dividend of $0.42. Pfizer’s dividend payout ratio is presently 232.43%.

Insider Transactions at Pfizer

In related news, Director Scott Gottlieb bought 1,000 shares of the stock in a transaction dated Wednesday, October 30th. The stock was acquired at an average price of $28.24 per share, for a total transaction of $28,240.00. Following the acquisition, the director now owns 10,000 shares in the company, valued at approximately $282,400. This represents a 11.11 % increase in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Corporate insiders own 0.06% of the company’s stock.

Institutional Investors Weigh In On Pfizer

Several hedge funds and other institutional investors have recently bought and sold shares of PFE. Gladius Capital Management LP increased its position in shares of Pfizer by 102.8% during the third quarter. Gladius Capital Management LP now owns 1,043 shares of the biopharmaceutical company’s stock worth $30,000 after purchasing an additional 38,015 shares in the last quarter. Quarry LP purchased a new position in Pfizer during the 2nd quarter worth approximately $31,000. Financial Connections Group Inc. acquired a new position in Pfizer during the second quarter worth approximately $34,000. Teachers Insurance & Annuity Association of America purchased a new stake in Pfizer in the third quarter valued at approximately $35,000. Finally, Joseph Group Capital Management boosted its holdings in shares of Pfizer by 168.3% in the third quarter. Joseph Group Capital Management now owns 1,229 shares of the biopharmaceutical company’s stock valued at $36,000 after acquiring an additional 771 shares during the period. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.